{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T21:42:35Z","timestamp":1776462155959,"version":"3.51.2"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.leukres.2013.01.021","type":"journal-article","created":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T18:33:06Z","timestamp":1362681186000},"page":"713-720","source":"Crossref","is-referenced-by-count":34,"title":["Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors"],"prefix":"10.1016","volume":"37","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2013.01.021_bib0005","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia \u2013 advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2013.01.021_bib0010","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/j.seminoncol.2011.11.002","article-title":"Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression","volume":"39","author":"Ernst","year":"2012","journal-title":"Sem Oncol"},{"key":"10.1016\/j.leukres.2013.01.021_bib0015","first-page":"543","article-title":"STI571: a gene product-targeted therapy for leukemia","volume":"29","author":"Mauro","year":"2001","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.leukres.2013.01.021_bib0020","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-years follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2013.01.021_bib0025","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.01.021_bib0030","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1185\/03007990903479299","article-title":"Management of chronic myeloid leukemia in clinical practice in France: results of the French subset of patients from the UNIC study","volume":"26","author":"Michallet","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.leukres.2013.01.021_bib0035","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.01.021_bib0040","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.01.021_bib0045","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.leukres.2013.01.021_bib0050","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2174\/156800912800190965","article-title":"Second-generation tyrosine kinase inhibitors as first-line treatment strategy in newly diagnosed chronic phase chronic myeloid leukemia patients","volume":"12","author":"Breccia","year":"2012","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.leukres.2013.01.021_bib0055","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.01.021_bib0060","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2009.011452","volume":"95","author":"Shah","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2013.01.021_bib0065","first-page":"S29","article-title":"Update: chronic myelogenous leukemia clinical practice guidelines","volume":"1","author":"O\u2019Brien","year":"2003","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.leukres.2013.01.021_bib0070","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cncr.25648","article-title":"Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: definitions and clinical implications","volume":"117","author":"Pinilla-Ibarz","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2013.01.021_bib0075","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2013.01.021_bib0080","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1182\/blood.V118.21.1700.1700","article-title":"Results of a phase II trial of dasatinib as frontline therapy for chronic myeloid leukemia (CML) in chronic phase","volume":"118","author":"Pemmaraju","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.01.021_bib0085","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2013.01.021_bib0090","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1182\/blood.V118.21.2756.2756","article-title":"Early CP, CML, nilotinib 400mg twice daily frontline: beyond 3 years, results remain excellent and stable (A GIMEMA CML Working Party trial)","volume":"118","author":"Gugliotta","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.01.021_bib0095","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2013.01.021_bib0100","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/cncr.11863","article-title":"The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase","volume":"100","author":"Sneed","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2013.01.021_bib0105","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.leukres.2011.09.018","article-title":"What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?","volume":"36","author":"Deininger","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2013.01.021_bib0110","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1182\/blood-2008-09-180604","article-title":"Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia","volume":"114","author":"Quintas-Cradama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.01.021_bib0115","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1182\/blood-2009-02-205328","article-title":"The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo","volume":"114","author":"Gratacap","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.01.021_bib0120","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1084\/jem.188.5.833","article-title":"Independent and opposing roles for Btk and lyn in B and myeloid signalling pathways","volume":"188","author":"Satterthwaite","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.leukres.2013.01.021_bib0125","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/ni893","article-title":"Essential role of Src-family protein tyrosine kinases in NF-kappaB activation during B cell development","volume":"4","author":"Saijo","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.leukres.2013.01.021_bib0130","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1182\/blood-2003-12-4396","article-title":"Perturbed myelo\/erytropoiesis in Lyn-deficient mice is similar to that in mice lacking the inhibitory phosphatises SHP-1 and SHIP-1","volume":"104","author":"Harder","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.01.021_bib0135","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/leu.2010.215","article-title":"Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"25","author":"Jabbour","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.01.021_bib0140","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1200\/jco.2011.29.15_suppl.6605","article-title":"Analysis of patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) who develop pleural effusion on first-line dasatinib: management and outcomes","volume":"29","author":"Launeville","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.01.021_bib0145","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure","volume":"25","author":"Quintas-Cradama","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.01.021_bib0150","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2008.07108.x","article-title":"Pleural effusions in patients with chronic myeloid leukemia treated with dasatinib may have an immune-mediated pathogenesis","volume":"141","author":"de Lavallade","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2013.01.021_bib0155","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","article-title":"Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy","volume":"23","author":"Mustjoki","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.01.021_bib0160","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/leu.2011.135","article-title":"Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation","volume":"25","author":"Kreutzman","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.01.021_bib0165","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V118.21.454.454","article-title":"Efficacy of frontline nilotinib therapy in patients (Pts) with newly diagnosed Philadelphia chromosome (Ph)-positive chronic myeloid leukemia in early chronic phase (CML-CP)","volume":"118","author":"Quintas-Cradama","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.01.021_bib0170","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/sj.leu.2404827","article-title":"UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia","volume":"21","author":"Singer","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.01.021_bib0175","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.leukres.2007.01.024","article-title":"Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib","volume":"31","author":"Breccia","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2013.01.021_bib0180","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1182\/blood.V110.11.4588.4588","article-title":"Analysis of glucose profiles in imatinib-resistant or intolerant chronic myelogenous leukemia (CML) patients treated with nilotinib: lack of correlation between glucose levels and nilotinib efficacy","volume":"110","author":"le Coutre","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.01.021_bib0185","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1182\/blood.V116.21.3430.3430","article-title":"Efficacy and safety of nilotinib in chronic phase (CP) chronic myeloid leukemia (CML) patients (pts) with type 2 diabetes in the ENESTnd trial","volume":"116","author":"Saglio","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.01.021_bib0190","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.leukres.2010.09.020","article-title":"Is imatinib-related cardiotoxicity still an open issue?","volume":"35","author":"Breccia","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2013.01.021_bib0195","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1161\/01.CIR.0000137913.26087.F0","article-title":"Prevalence and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999\u20132000","volume":"110","author":"Selvin","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.leukres.2013.01.021_bib0200","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2013.01.021_bib0205","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djr292","article-title":"Severe peripheral arterial disease during nilotinib therapy","volume":"103","author":"le Coutre","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.leukres.2013.01.021_bib0210","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.2753.2753","article-title":"Nilotinib exerts direct effects on vascular endothelial cells nad may act as a co-trigger of atherosclerosis in patients with Ph+ CML","volume":"118","author":"Hadzijusufovic","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.01.021_bib0215","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.2757.2757","article-title":"Retrospective cohort analysis of peripheral arterial occlusive disease (PAOD) events in patients with chronic myeloid leukemia in chronic phase (CML-CP)","volume":"118","author":"Giles","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.01.021_bib0220","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ahj.2011.05.012","article-title":"Current therapeutics and practical management strategies for pulmonary arterial hypertension","volume":"162","author":"Agarwal","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.leukres.2013.01.021_bib0225","unstructured":"EMEA: Sprycel-Scientific discussion. European Public Assessment Report (EPAR 2011)."},{"key":"10.1016\/j.leukres.2013.01.021_bib0230","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.leukres.2008.09.026","article-title":"Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia","volume":"33","author":"Rasheed","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2013.01.021_bib0235","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/bmt.2008.415","article-title":"Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient","volume":"43","author":"Mattei","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.leukres.2013.01.021_bib0240","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1183\/09031936.00154210","article-title":"Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukemia","volume":"38","author":"Dumitrescu","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.leukres.2013.01.021_bib0245","first-page":"11","article-title":"Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?","volume":"23","author":"Hennigs","year":"2011","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.leukres.2013.01.021_bib0250","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.leukres.2011.08.007","article-title":"Reversible pulmonary arterial hypertension likely related to long-term, low dose dasatinib treatment for chronic myeloid leukemia","volume":"36","author":"Orlandi","year":"2012","journal-title":"Leuk Res"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613000374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613000374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T10:50:18Z","timestamp":1595501418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212613000374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0145212613000374"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2013.01.021","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}